EYPT Q1 2025 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+109.3% YoY

Gross Profit

$24M96.7% margin

Operating Income

-$49M-199.7% margin

Net Income

-$45M-184.8% margin

EPS (Diluted)

$-0.65

QoQ Revenue Growth

+111.0%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$53M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$363M

Total Liabilities

$64M

Stockholders' Equity

$298M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$12M	+109.3%
Gross Profit	$24M	$11M	+116.5%
Operating Income	-$49M	-$33M	-46.6%
Net Income	-$45M	-$29M	-54.3%

Revenue Segments

Royalty

$13M51%

License And Collaboration Agreement

$11M44%

Product

$715,0003%

Y U T I Q Product

$600,0002%